Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy

Posts tagged ‘osimertinib’

What science tells us about future directions in lung cancer

The World Conference on Lung Cancers (WCLC) annual meeting in Singapore showcased important scientific findings illuminating new directions against these deadly diseases.

While some clinical presentations fell a little short of expectations, smaller sessions revealed some important gems illustrating the intricacies of lung cancer biology where art and science intersect.

In the end lung cancer remains complex, heterogeneous, often aggressive, and evolving. Emerging translational research undoubtedly brings hope towards guiding more targeted therapeutic strategies.

The art is in creatively leveraging emerging science to tackle these lethal diseases from every angle.

Here we highlight seven areas where we ought to be paying attention to when considering future directions in lung cancer…

To continue reading our latest highlights on oncology new product development including commentary and analysis, BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

A flurry of new biomarkers are coming to the fore

Jockeying for position

Our latest post discusses recent updates on biomarker research across several cancer types.

These include several types of lung cancer, as well as prostate cancer, colorectal cancer, and bladder cancer.

Not all the trials mentioned returned a positive result, although some were much more encouraging. Either way, there is much to learn from the analyses and offer some pointers for the future.

Also included are a dozen or so pharma or biotech companies whose work might be impacted by the findings described within. Yours could be one of them…

To continue reading our latest highlights on oncology new product development including commentary and analysis, BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

What’s hot in lung cancer?

Gardens by the Bay in Singapore

With the abstract titles now available for the World Congress in Lung Cancer (WCLC), it’s time to take a look at what we can expect for the meeting coming up in early September.

In our latest conference Preview, we have highlighted several education sessions to look at, as well as ten key oral presentations to watch out for…

To continue reading our latest highlights on oncology new product development including commentary and analysis, BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Are the lions roaring in Chicago?

Are the lions roaring in Chicago?

In our latest coverage from the annual meeting at ASCO we explore and discuss some of the highlights from Day 1 of the meeting.

It used to be Friday was reserved for the educational events and Saturday was the start of various oral sessions.

Increasingly, the meeting has now become so jam packed we now see a number of tumour type oral sessions on Friday and a wave of posters on Saturday.

We asked ourselves what were the controversies and findings that stood out from pack and why do they matter?

To continue reading our latest highlights on oncology new product development including commentary and analysis, BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

AACR23 – Is there an ADC renaissance on the horizon?

Orlando – the AACR annual meeting provides a window into future cancer drug development, and this year’s meeting is no exception.

As AACR23 comes to an end in sunny Orlando, we’re taking a closer look at the next generation of ADC’s in early development and some of the data presented at AACR23.

Companies are always looking for new ways to overcome resistance pathways or provide novel combination strategies. Will the next generation compounds in development lead to a continued renaissance in the ADC field?

There’s certainly plenty to think about if you are a new products or business development professional…

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Reflections on ESMO22

Vive La France! 

Despite the raft of negative trials presented in Paris this year, it wasn’t all bad news, although for a while it certainly seemed this way with quite a few phase 3 trials missing their primary endpoints.

It’s time for our ESMO review where we highlight no less than 10 trials offering positive vibes and encouraging signals, particularly in early stage development.

So what were the standouts and why do they matter?

To continue reading our latest discussion on oncology new product development plus commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

The road to Damascus is paved with good intentions

Münze Österreich

The World Conference on Lung Cancer (WCLC) is underway in Vienna, and for those who arrived early, Friday was the hottest day of the year (37°C) so far!

Is the data at the meeting as hot as the summer weather?

Companies undertake drug development with the best of intentions, but there comes a moment in time where you have to take stock of what exactly is the data is telling you?

Did we experience an epiphany or turning point at WCLC for KRAS G12C inhibitors in lung cancer? Or is there still a way to be travelled on the road to Damascus?

In this latest post we take a look at some key data presented during the meeting and what it means for those in this space.

It’s a story we’ve been following for some time, and as always, there are nuances to be had, because it’s far from black or white…

To continue reading our latest discussion on oncology new product development plus commentary and analysis, BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

 

Addressing acquired resistance through novel combination strategies

Sometimes it may seem as though the hottest – and often only things – which get attention these days are IO related, while the good old fashioned targeted therapies are ignored.

St Charles Streetcar, New Orleans LA

Do so at your peril, folks, because there’s a lot of useful data coming through these days exploring novel combination approaches to overcome acquired resistance and improve outcomes for people with various advanced cancers!

In this post, we take a look at some emerging preclinical data from the annual meeting of AACR in New Orleans, which either has led to new early stage combination trials in people with certain advanced cancers or will be starting soon.

The good news is the science is solid and the need for novel combinations in these settings is a high one – it’s time to get on board and learn about these important developments…

BSB subscribers can read our latest conference coverage from AACR plus commentary and analysis – you can either log-in or click to access.

This content is restricted to subscribers

New developments in the protein degradation niche

Degron (red)  Credit: Dmeyer314 via wikipedia

One of the emerging hot areas in cancer research these days is the field of protein degradation, which finally seems to have come of age.

This also means plenty of opportunities to discuss new developments as they evolve.

So what’s new and why are the latest updates important?

BSB subscribers can read more on our latest look at targeted protein degradation related topics – you can log-in or click to access our ongoing oncology coverage.

This content is restricted to subscribers

Emerging developments and trends in advanced lung cancer

Gems from the poster halls are always a popular series at cancer conferences where we highlight emerging early stage agents of interest.

Not every oncology development has gone to the dogs – there are some gems out there too

This time around we look at some data from a China biotech, another peek at TIGIT, resistance to a targeted therapy, a novel antibody target and a real world study, which both inspired and caught my attention.

As always with oncology R&D it isn’s always plain sailing – there are sometimes some surprising results (good and bad), spanners in the works and also some really useful trial designs to consider.

What can we learn from the latest round of presentations?

Let’s roll!

To learn more about the early stage data and get a heads up on our latest oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

error: Content is protected !!